Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of […]
There are currently no biologic treatment options available for patients with psoriatic arthritis (PsA) who are non-responsive to traditional non-biologic DMARDs and TNF inhibitors. Interleukins (IL) 12 and 23 have been implicated in the pathogenesis of plaque psoriasis. A humanized monoclonal antibody directed against these cytokines, ustekinumab, has demonstrated efficacy in the treatment of psoriasis […]
The spondyloarthropathies (SpA) are a group of related conditions that include ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, the arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy. Axial involvement (i.e. axial SpA) in these disorders tends to be slowly progressive, requiring in many cases years to decades of clinical symptoms to develop radiographic manifestations.
On February 19, 2009, the US Food and Drug Administration (FDA) approved the licensing of febuxostat for the treatment of hyperuricemia in patients with chronic gout. This is the only approved indication for the drug at this time. Febuxostat will be marketed under the trade name Uloric and is manufactured by Takeda Pharmaceuticals. Links to […]
The efficacy of glucosamine and/or chondroitins in knee osteoarthritis (OA) has been controversial. A recent large, randomized, multicenter trial (the GAIT trial) found no symptomatic or structure-modifying benefit of glucosamine or chondroitin, alone or in combination. However, prior studies conducted in Europe using different formulations have suggested the possibility of structure modification with chondroitin sulfate […]
Cases of new onset psoriasis in patients receiving TNF inhibitors for the treatment of rheumatoid arthritis (RA) have been reported; however, case reports do not permit the calculation of drug-associated incidence rates. Here, Harrison et al (Ann Rheum Dis 2009; 68: 209) compare incident psoriasis in TNF inhibitor treated vs. untreated patients enrolled in the […]
Greater strength of the quadriceps muscles supporting the knee has been associated with decreased pain and better knee function in individuals with knee osteoarthritis (OA); however, whether higher quadriceps strength prevents further cartilage loss has yielded mixed results.
RA patients who use methotrexate have been shown to have lower cardiovascular mortality compared to non-users; however, the mechanism underlying this protection is unclear.
RA patients who use methotrexate have been shown to have lower cardiovascular mortality compared to non-users; however, the mechanism underlying this protection is unclear. Here, Reiss et al (Arthritis Rheum 2008; 58(12): 3675) explore the atheroprotective effects of methotrexate in an experimental model of atherogenesis. Methods THP-1 monocytes/macrophages and human donor peripheral blood mononuclear cells […]
The efficacy of rituximab, a monoclonal antibody directed against CD20 positive B cells, has been demonstrated for the treatment of rheumatoid arthritis (RA) in a number of key studies. However, not all patients respond to therapy. Whether patients with initial non-response may benefit from follow-up treatments (i.e. initial treatment resistance) has not been investigated.